Alliance for Pandemic Preparedness
April 21, 2021
A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report
Category: Article Summary
Topic: Vaccines and Immunity
Keywords (Tags): vaccine
- [Pre-print, not peer-reviewed] A real-world study of the safety and immunogenicity of one dose of the Covishield (Oxford-AstraZeneca) vaccine among healthcare workers in India (n = 1,638) found that 79.0% were seropositive 2 weeks after the 1st dose, an increase from the 48.2% who were seropositive at baseline. Among those with prior infection, 98.2% were seropositive. No serious adverse events were reported. [Editorial Note: Covishield is the trade name of the Oxford-Astrazeneca ChadOx1 vaccine AZD1222 that is manufactured in India].
Kataria et al. (Apr 20, 2021). A Real World Evaluation of the Safety and Immunogenicity of the Covishield Vaccine ChAdOx1 NCoV- 19 Corona Virus Vaccine (Recombinant) in Health Care Workers (HCW) in National Capital Region (NCR) of India A Preliminary Report. Pre-print downloaded Apr 21 from https://doi.org/10.1101/2021.04.14.21255452